Shanghai Junshi Bioscience Co., Ltd.
Clinical trials sponsored by Shanghai Junshi Bioscience Co., Ltd., explained in plain language.
-
New hope for lung cancer patients who stopped responding to standard therapy
Disease control Not yet recruitingThis study tests two experimental drugs, JS212 and JS111, together in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. About 35 adults will join to find the safest dose and …
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New hope for advanced lung cancer: experimental combo therapy enters phase 2
Disease control Not yet recruitingThis study tests a new drug called JS212, combined with other treatments, in people with advanced lung cancer. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will take part, and the study is not yet recruiting.
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 03:00 UTC